Sort
10,766 grants matching “checkpoint inhibitor”
Structure and function of RAD51 paralog tumor suppressor complexes in genome maintenance
$640,408Shaun Olsen · University Of Texas Hlth Science Center · R01 · FY2025 · CA
Ascorbic acid as a pharmacologic agent in disease treatment
$640,390Mark A Levine · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Uncovering the metabolic underpinnings of T cell exhaustion
$640,384Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AI
Uncovering the metabolic underpinnings of T cell exhaustion
$640,384Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · AI
The Genetics of Ocular Melanoma
$640,346Anne Mary Bowcock · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
$640,182Harry H Yoon · Mayo Clinic Rochester · R01 · FY2021 · CA
Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia
$640,103Peter Kurre · Children'S Hosp Of Philadelphia · R01 · FY2023 · HL
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer
$639,862Mitch A Phelps · Ohio State University · R01 · FY2022 · CA
Synthetic lethalities to cell cycle disruption in glioma
$639,818Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck
$639,614Dong Moon Shin · Emory University · R01 · FY2024 · CA
Strategies for Cancer Immunotherapy Clinical Trials
$639,565Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Strategies for Therapeutic Cancer Vaccine Clinical Trials
$639,402Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment
$639,351Yubin Miao · University Of Colorado Denver · R01 · FY2023 · CA
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers
$639,330France Carrier · University Of Maryland Baltimore · R01 · FY2024 · CA
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers
$639,330France Carrier · University Of Maryland Baltimore · R01 · FY2025 · CA
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
$639,268Harry H Yoon · Mayo Clinic Rochester · R01 · FY2022 · CA
Mechanisms of BET bromodomain metabolic reprogramming in triple negative breast cancer
$639,256Gerald V Denis · Boston University Medical Campus · R01 · FY2020 · CA
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer
$639,109Keith L Knutson · Mayo Clinic Jacksonville · R01 · FY2025 · CA
A model for predicting response to PD-1 inhibitors in NSCLC
$639,083Edward B Garon · University Of California Los Angeles · R01 · FY2017 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression
$639,040Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2024 · CA
NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastoma
$639,004Jian Campian · Mayo Clinic Rochester · R01 · FY2025 · CA
A novel preclinical model of spontaneous metastasis
$638,924Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Understanding the role of autophagy-regulated cell death in the escape from replicative crisis
$638,770Jan Karlseder · Salk Institute For Biological Studies · R01 · FY2021 · CA
Understanding the role of autophagy-regulated cell death in the escape from replicative crisis
$638,770Jan Karlseder · Salk Institute For Biological Studies · R01 · FY2020 · CA
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy
$638,608Donald Ym Leung · National Jewish Health · U01 · FY2020 · AR